Arvinas Inc

NASDAQ:ARVNUnited States

Arvinas, Inc. is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The Company uses its PROTAC Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC targeted protein degraders, that are designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. It has four investigational clinical-stage programs: vepdegestrant (ARV-471) for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer; ARV-766 and bavdegalutamide for the treatment of men with metastatic castration-resistant prostate cancer, and ARV-102 for the treatment of patients with neurodegenerative disorders. Its product candidate, ARV-393, is designed to target the B-cell lymphoma 6, or BCL6 protein.

Contact Information

Headquarters

5 Science ParkNEW HAVEN, CT, United States 06511-1966

Phone

203-535-1456

Fax

302-636-5454

Executives

Chairman of the Board, President, Chief Executive Officer

John Houston

Chief Financial Officer, Treasurer

Andrew Saik

President - Research and Development

Ian Taylor

Chief Scientific Officer

Angela Cacace

General Counsel

Jared Freedberg